Geopolitics & Antimicrobial Resistance: A Global Threat
- The landscape of research funding frequently enough involves navigating potential competing interests.
- has also received research grants from the National Institute for Health and Care Research (2013–2025), CW+ Charity (2018–2025), North West London Pathology (2022–2024), LifeArc (2020–2022), Shionogi (2024–2025), Infectopharm...
- also plays a role in research, having received research grants from the Drummond Foundation, the john Muir Trust, and the Healthcare Infection Society.
Dive into the complex world of research funding and competing interests, a critical aspect of scientific integrity. L.S.P.M. takes a significant role, consulting for numerous pharmaceutical companies from 2013 to 2025, including bioMerieux, Pfizer, and Gilead, providing crucial expertise. Moreover, L.S.P.M. received grants from institutions like the National Institute for Health and Care Research, supporting diverse research projects. S.J.C.P., also a key player, contributed through research grants and a parliamentary internship.Navigating these interests is crucial for clarity. News Directory 3 highlights this interplay. Disclosure and ethical guidelines are central. Discover what’s next in this evolving landscape.
Navigating Competing Interests in Research funding
updated June 18, 2025
The landscape of research funding frequently enough involves navigating potential competing interests. L.S.P.M. has a significant role in this area, having consulted for bioMerieux (2013-2025), Eumedica (2016–2025), Pfizer (2018–2025), Sumitovant (2021–2023), shionogi (2021–2025), Qiagen (2023), Gilead (2024), BioNTech (2024), Insmed (2024) and Advanz (2024–2025). These consultations involve providing expertise and guidance to these companies.
In addition to consulting, L.S.P.M. has also received research grants from the National Institute for Health and Care Research (2013–2025), CW+ Charity (2018–2025), North West London Pathology (2022–2024), LifeArc (2020–2022), Shionogi (2024–2025), Infectopharm (2022–2024), the Joint Programming Initiative on AntiMicrobial Resistance (2023–2025) and the Healthcare Infection Society (2024–2025). These grants support various research projects.
S.J.C.P. also plays a role in research, having received research grants from the Drummond Foundation, the john Muir Trust, and the Healthcare Infection Society. Moreover, S.J.C.P. served as a parliamentary intern to the office of Dr.Danny Chambers, MP, on behalf of the British Society for Antimicrobial Chemotherapy.
What’s next
Understanding and disclosing these competing interests is crucial for maintaining transparency and integrity in research. Future discussions will likely focus on refining guidelines and practices to ensure objectivity in research outcomes.